Table 1.
Literature evidence of drugs that can be repurposed to target SARS-CoV-2-interacting proteins.
| Drug | Targets interacting with SARS-CoV-2 | Literature/clinical trial evidence |
|---|---|---|
| sirolimus | PSMA2,ACSL3,SCARB1,PLOD2,POLA1,XPO1,COMT,BCL2L2,IKBKB,CHEK2,PPIA,GLA,SIGMAR1,IDE | clinical trial: NCT04341675 |
| irbesartan | BCL2,GFER,IKBKB,SIRT5,NARS2 | PMID: 32129518 |
| ribavirin | ATP6V1A,PLOD2,BCL2,GGCX,BCL2L2,IMPDH2 | PMID: 32227493 |
| apicidin | PSMA2,DNMT1,SCARB1,PLAT,PLOD2,ATF5,PCSK6,COMT,CHEK2,RTN4,SIGMAR1,HDAC2 | PMID: 32353859 |
| azacitidine | PSMA2,JUN,SCARB1,ABCC1,PRKAR2B,PCSK6,COMT,CHEK2,F2RL1,BRD2 | PMID: 32353859 |
| entacapone | JUN,DNMT1,PRKACA,ABCC1,COMT,F2RL1,TBK1 | PMID: 32353859 |
| mercaptopurine | DNMT1,SCARB1,HDAC2,PRKAR2B,XPO1,COMT,PPIA,IDE,NARS2 | PMID: 18313035,PMID: 25542975,PMID: 19374142 |
| ruxolitinib | MARK2 | PMID: 32353859 |
| midostaurin | MARK2 | PMID: 32353859 |
| oseltamivir | NEU1 | DOI: https://doi.org/10.1016/S2214-109X(20)30114-5 |
| valproic acid | HDAC2 | PMID: 32353859 |
| lisinopril | ACE2 | doi: 10.1001/jamacardio.2020.1624 |
| mycophenolic acid | IMPDH2 | approved drug |
| camostat | PRSS1 | clinical trial: NCT04353284 |
| silmitasertib | CSNK2A2 | PMID: 32353859 |
| metformin hydrochloride | NDUFAF2,NDUFAF1,NDUFB9 | PMID: 32360697, PMID: 32347974 |
| fedratinib | BRD4 | PMID: 32205092 |
| nafamostat | PRSS1 | DOI: 10.1128/AAC.00754-20 |
| gemcitabine hydrochloride | POLA1 | https://www.cebm.net/COVID-19/registered-trials-and-analysis/ |
| migalastat | GLA | PMID: 32353859 |
| chloroquine | ACE2 | PMID: 32074550 |
| daunorubicin | ABCC1 | Chemrxiv: https://orcid.org/0000-0002-4745-366X |
| ponatinib | RIPK1 | PMID: 32353859 |